{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:18:26Z","timestamp":1762431506417,"version":"3.41.0"},"reference-count":188,"publisher":"Bentham Science Publishers Ltd.","issue":"34","funder":[{"DOI":"10.13039\/501100004895","name":"European Social Fund GINOP","doi-asserted-by":"publisher","award":["GINOP-2.3.2-15-2016-00034"],"award-info":[{"award-number":["GINOP-2.3.2-15-2016-00034"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commissio","doi-asserted-by":"publisher","award":["602633"],"award-info":[{"award-number":["602633"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003825","name":"Hungarian Brain Research Program","doi-asserted-by":"publisher","award":["KTIA_13_NAPA-III\/9"],"award-info":[{"award-number":["KTIA_13_NAPA-III\/9"]}],"id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2019,12,12]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Migraine is one of the most disabling neurological conditions and associated with high socio-economic costs. Though certain aspects of the pathomechanism of migraine are still incompletely understood, the leading hypothesis implicates the role of the activation of the trigeminovascular system. Triptans are considered to be the current gold standard therapy for migraine attacks; however, their use in clinical practice is limited. Prophylactic treatment includes non-specific approaches for migraine prevention. All these support the need for future studies in order to develop innovative anti-migraine drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>The present study is a review of the current literature regarding new therapeutic lines in migraine research.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>A systematic literature search in the database of PUBMED was conducted concerning therapeutic strategies in a migraine published until July 2017.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Ongoing clinical trials with 5-HT1F receptor agonists and glutamate receptor antagonists offer promising new aspects for acute migraine treatment. Monoclonal antibodies against CGRP and the CGRP receptor are revolutionary in preventive treatment; however, further long-term studies are needed to test their tolerability. Preclinical studies show positive results with PACAP- and kynurenic acid-related treatments. Other promising therapeutic strategies (such as those targeting TRPV1, substance P, NOS, or orexin) have failed to show efficacy in clinical trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Due to their side-effects, current therapeutic approaches are not suitable for all migraine patients. Especially frequent episodic and chronic migraine represents a therapeutic challenge for researchers. Clinical and preclinical studies are needed to untangle the pathophysiology of migraine in order to develop new and migraine-specific therapies.<\/jats:p><\/jats:sec>","DOI":"10.2174\/0929867325666180530114534","type":"journal-article","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T07:34:58Z","timestamp":1527752098000},"page":"6261-6281","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Therapeutic Impact of New Migraine Discoveries"],"prefix":"10.2174","volume":"26","author":[{"given":"L\u00e1szl\u00f3","family":"V\u00e9csei","sequence":"first","affiliation":[{"name":"Department of Neurology, University of Szeged, Szeged, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda","family":"Luk\u00e1cs","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Szeged, Szeged, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e1nos","family":"Tajti","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Szeged, Szeged, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferenc","family":"F\u00fcl\u00f6p","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Chemistry and MTA-SZTE Research Group for Stereochemistry, University of Szeged, Szeged, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f3zsef","family":"Toldi","sequence":"additional","affiliation":[{"name":"Department of Physiology, Anatomy and Neuroscience, University of Szeged, Szeged, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Edvinsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Division of Experimental Vascular Research, Lund University, Lund, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(12)61689-4","volume":"380","author":"Murray C.J.","year":"2012","unstructured":"Murray C.J.; Vos T.; Lozano R.; Naghavi M.; Flaxman A.D.; Michaud C.; Ezzati M.; Shibuya K.; Salomon J.A.; Abdalla S.; Aboyans V.; Abraham J.; Ackerman I.; Aggarwal R.; Ahn S.Y.; Ali M.K.; Alvarado M.; Anderson H.R.; Anderson L.M.; Andrews K.G.; Atkinson C.; Baddour L.M.; Bahalim A.N.; Barker-Collo S.; Barrero L.H.; Bartels D.H.; Bas\u00e1\u00f1ez M.G.; Baxter A.; Bell M.L.; Benjamin E.J.; Bennett D.; Bernab\u00e9 E.; Bhalla K.; Bhandari B.; Bikbov B.; Bin Abdulhak A.; Birbeck G.; Black J.A.; Blencowe H.; Blore J.D.; Blyth F.; Bolliger I.; Bonaventure A.; Boufous S.; Bourne R.; Boussinesq M.; Braithwaite T.; Brayne C.; Bridgett L.; Brooker S.; Brooks P.; Brugha T.S.; Bryan-Hancock C.; Bucello C.; Buchbinder R.; Buckle G.; Budke C.M.; Burch M.; Burney P.; Burstein R.; Calabria B.; Campbell B.; Canter C.E.; Carabin H.; Carapetis J.; Carmona L.; Cella C.; Charlson F.; Chen H.; Cheng A.T.; Chou D.; Chugh S.S.; Coffeng L.E.; Colan S.D.; Colquhoun S.; Colson K.E.; Condon J.; Connor M.D.; Cooper L.T.; Corriere M.; Cortinovis M.; de Vaccaro K.C.; Couser W.; Cowie B.C.; Criqui M.H.; Cross M.; Dabhadkar K.C.; Dahiya M.; Dahodwala N.; Damsere-Derry J.; Danaei G.; Davis A.; De Leo D.; Degenhardt L.; Dellavalle R.; Delossantos A.; Denenberg J.; Derrett S.; Des Jarlais D.C.; Dharmaratne S.D.; Dherani M.; Diaz-Torne C.; Dolk H.; Dorsey E.R.; Driscoll T.; Duber H.; Ebel B.; Edmond K.; Elbaz A.; Ali S.E.; Erskine H.; Erwin P.J.; Espindola P.; Ewoigbokhan S.E.; Farzadfar F.; Feigin V.; Felson D.T.; Ferrari A.; Ferri C.P.; F\u00e8vre E.M.; Finucane M.M.; Flaxman S.; Flood L.; Foreman K.; Forouzanfar M.H.; Fowkes F.G.; Fransen M.; Freeman M.K.; Gabbe B.J.; Gabriel S.E.; Gakidou E.; Ganatra H.A.; Garcia B.; Gaspari F.; Gillum R.F.; Gmel G.; Gonzalez-Medina D.; Gosselin R.; Grainger R.; Grant B.; Groeger J.; Guillemin F.; Gunnell D.; Gupta R.; Haagsma J.; Hagan H.; Halasa Y.A.; Hall W.; Haring D.; Haro J.M.; Harrison J.E.; Havmoeller R.; Hay R.J.; Higashi H.; Hill C.; Hoen B.; Hoffman H.; Hotez P.J.; Hoy D.; Huang J.J.; Ibeanusi S.E.; Jacobsen K.H.; James S.L.; Jarvis D.; Jasrasaria R.; Jayaraman S.; Johns N.; Jonas J.B.; Karthikeyan G.; Kassebaum N.; Kawakami N.; Keren A.; Khoo J.P.; King C.H.; Knowlton L.M.; Kobusingye O.; Koranteng A.; Krishnamurthi R.; Laden F.; Lalloo R.; Laslett L.L.; Lathlean T.; Leasher J.L.; Lee Y.Y.; Leigh J.; Levinson D.; Lim S.S.; Limb E.; Lin J.K.; Lipnick M.; Lipshultz S.E.; Liu W.; Loane M.; Ohno S.L.; Lyons R.; Mabweijano J.; MacIntyre M.F.; Malekzadeh R.; Mallinger L.; Manivannan S.; Marcenes W.; March L.; Margolis D.J.; Marks G.B.; Marks R.; Matsumori A.; Matzopoulos R.; Mayosi B.M.; McAnulty J.H.; McDermott M.M.; McGill N.; McGrath J.; Medina-Mora M.E.; Meltzer M.; Mensah G.A.; Merriman T.R.; Meyer A.C.; Miglioli V.; Miller M.; Miller T.R.; Mitchell P.B.; Mock C.; Mocumbi A.O.; Moffitt T.E.; Mokdad A.A.; Monasta L.; Montico M.; Moradi-Lakeh M.; Moran A.; Morawska L.; Mori R.; Murdoch M.E.; Mwaniki M.K.; Naidoo K.; Nair M.N.; Naldi L.; Narayan K.M.; Nelson P.K.; Nelson R.G.; Nevitt M.C.; Newton C.R.; Nolte S.; Norman P.; Norman R.; O\u2019Donnell M.; O\u2019Hanlon S.; Olives C.; Omer S.B.; Ortblad K.; Osborne R.; Ozgediz D.; Page A.; Pahari B.; Pandian J.D.; Rivero A.P.; Patten S.B.; Pearce N.; Padilla R.P.; Perez-Ruiz F.; Perico N.; Pesudovs K.; Phillips D.; Phillips M.R.; Pierce K.; Pion S.; Polanczyk G.V.; Polinder S.; Pope C.A.; Popova S.; Porrini E.; Pourmalek F.; Prince M.; Pullan R.L.; Ramaiah K.D.; Ranganathan D.; Razavi H.; Regan M.; Rehm J.T.; Rein D.B.; Remuzzi G.; Richardson K.; Rivara F.P.; Roberts T.; Robinson C.; De Le\u00f2n F.R.; Ronfani L.; Room R.; Rosenfeld L.C.; Rushton L.; Sacco R.L.; Saha S.; Sampson U.; Sanchez-Riera L.; Sanman E.; Schwebel D.C.; Scott J.G.; Segui-Gomez M.; Shahraz S.; Shepard D.S.; Shin H.; Shivakoti R.; Singh D.; Singh G.M.; Singh J.A.; Singleton J.; Sleet D.A.; Sliwa K.; Smith E.; Smith J.L.; Stapelberg N.J.; Steer A.; Steiner T.; Stolk W.A.; Stovner L.J.; Sudfeld C.; Syed S.; Tamburlini G.; Tavakkoli M.; Taylor H.R.; Taylor J.A.; Taylor W.J.; Thomas B.; Thomson W.M.; Thurston G.D.; Tleyjeh I.M.; Tonelli M.; Towbin J.A.; Truelsen T.; Tsilimbaris M.K.; Ubeda C.; Undurraga E.A.; van der Werf M.J.; van Os J.; Vavilala M.S.; Venketasubramanian N.; Wang M.; Wang W.; Watt K.; Weatherall D.J.; Weinstock M.A.; Weintraub R.; Weisskopf M.G.; Weissman M.M.; White R.A.; Whiteford H.; Wiebe N.; Wiersma S.T.; Wilkinson J.D.; Williams H.C.; Williams S.R.; Witt E.; Wolfe F.; Woolf A.D.; Wulf S.; Yeh P.H.; Zaidi A.K.; Zheng Z.J.; Zonies D.; Lopez A.D.; AlMazroa M.A.; Memish Z.A.; Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012,380(9859),2197-2223","journal-title":"Lancet"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/brain\/awt320","volume":"137","author":"Maniyar F.H.","year":"2014","unstructured":"Maniyar F.H.; Sprenger T.; Monteith T.; Schankin C.; Goadsby P.J.; Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain 2014,137(Pt 1),232-241","journal-title":"Brain"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1001\/archneurpsyc.1941.02280200137007","volume":"46","year":"1941","unstructured":"K.S.L. Patterns of cerebral integration indicated by the scotomas of migraine. Arch Neurol Psychiatry 1941,46,331-339","journal-title":"Arch Neurol Psychiatry"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/00325481.2016.1175912","volume":"128","author":"Silberstein S.D.","year":"2016","unstructured":"Silberstein S.D.; Considerations for management of migraine symptoms in the primary care setting. Postgrad Med 2016,128(5),523-537","journal-title":"Postgrad Med"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1177\/0333102415593089","volume":"36","author":"Viana M.","year":"2016","unstructured":"Viana M.; Linde M.; Sances G.; Ghiotto N.; Guaschino E.; Allena M.; Terrazzino S.; Nappi G.; Goadsby P.J.; Tassorelli C.; Migraine aura symptoms: Duration, succession and temporal relationship to headache. Cephalalgia 2016,36(5),413-421","journal-title":"Cephalalgia"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S1474-4422(11)70048-5","volume":"10","author":"Russell M.B.","year":"2011","unstructured":"Russell M.B.; Ducros A.; Sporadic and familial hemiplegic migraine: pathophysiological mechanisms, clinical characteristics, diagnosis, and management. Lancet Neurol 2011,10(5),457-470","journal-title":"Lancet Neurol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"33","year":"2013","unstructured":"Headache Classification Committee of the International Headache, S., The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013,33(9),629-808","journal-title":"Cephalalgia"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1046\/j.1468-2982.1991.1105229.x","volume":"11","author":"Blau J.N.","year":"1991","unstructured":"Blau J.N.; Migraine postdromes: symptoms after attacks. Cephalalgia 1991,11(5),229-231","journal-title":"Cephalalgia"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1212\/WNL.0000000000002789","volume":"87","author":"Giffin N.J.","year":"2016","unstructured":"Giffin N.J.; Lipton R.B.; Silberstein S.D.; Olesen J.; Goadsby P.J.; The migraine postdrome: An electronic diary study. Neurology 2016,87(3),309-313","journal-title":"Neurology"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1177\/0333102411398152","volume":"31","author":"Edvinsson L.","year":"2011","unstructured":"Edvinsson L.; Tracing neural connections to pain pathways with relevance to primary headaches. Cephalalgia 2011,31(6),737-747","journal-title":"Cephalalgia"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/j.1468-2982.2008.01829.x","volume":"29","author":"Liu Y.","year":"2009","unstructured":"Liu Y.; Broman J.; Zhang M.; Edvinsson L.; Brainstem and thalamic projections from a craniovascular sensory nervous centre in the rostral cervical spinal dorsal horn of rats. Cephalalgia 2009,29(9),935-948","journal-title":"Cephalalgia"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/BF00237586","volume":"61","author":"Mokha S.S.","year":"1986","unstructured":"Mokha S.S.; McMillan J.A.; Iggo A.; Pathways mediating descending control of spinal nociceptive transmission from the nuclei locus coeruleus (LC) and raphe magnus (NRM) in the cat. Exp Brain Res 1986,61(3),597-606","journal-title":"Exp Brain Res"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/0306-4522(93)90264-G","volume":"54","author":"Li Y.Q.","year":"1993","unstructured":"Li Y.Q.; Takada M.; Shinonaga Y.; Mizuno N.; Direct projections from the midbrain periaqueductal gray and the dorsal raphe nucleus to the trigeminal sensory complex in the rat. Neuroscience 1993,54(2),431-443","journal-title":"Neuroscience"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.pain.2011.11.029","volume":"153","author":"Szab\u00f3 N.","year":"2012","unstructured":"Szab\u00f3 N.; Kincses Z.T.; P\u00e1rdutz A.; Tajti J.; Szok D.; Tuka B.; Kir\u00e1ly A.; Babos M.; V\u00f6r\u00f6s E.; Bomboi G.; Orzi F.; V\u00e9csei L.; White matter microstructural alterations in migraine: a diffusion-weighted MRI study. Pain 2012,153(3),651-656","journal-title":"Pain"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S1474-4422(13)70067-X","volume":"12","author":"Amin F.M.","year":"2013","unstructured":"Amin F.M.; Asghar M.S.; Hougaard A.; Hansen A.E.; Larsen V.A.; de Koning P.J.; Larsson H.B.; Olesen J.; Ashina M.; Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. Lancet Neurol 2013,12(5),454-461","journal-title":"Lancet Neurol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.npep.2015.03.006","volume":"52","author":"Tajti J.","year":"2015","unstructured":"Tajti J.; Szok D.; Majl\u00e1th Z.; Tuka B.; Cs\u00e1ti A.; V\u00e9csei L.; Migraine and neuropeptides. Neuropeptides 2015,52,19-30","journal-title":"Neuropeptides"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nrn3617","volume":"15","author":"Xanthos D.N.","year":"2014","unstructured":"Xanthos D.N.; Sandk\u00fchler J.; Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity. Nat Rev Neurosci 2014,15(1),43-53","journal-title":"Nat Rev Neurosci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/nn.3144","volume":"15","author":"Chiu I.M.","year":"2012","unstructured":"Chiu I.M.; von Hehn C.A.; Woolf C.J.; Neurogenic inflammation and the peripheral nervous system in host defense and immunopathology. Nat Neurosci 2012,15(8),1063-1067","journal-title":"Nat Neurosci"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/j.pain.2013.07.021","volume":"154","author":"Noseda R.","year":"2013","unstructured":"Noseda R.; Burstein R.; Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain. Pain 2013,154(Suppl. 1),S44-S53","journal-title":"Pain"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"8807","DOI":"10.1523\/JNEUROSCI.0511-10.2010","volume":"30","author":"Zhang X.","year":"2010","unstructured":"Zhang X.; Levy D.; Noseda R.; Kainz V.; Jakubowski M.; Burstein R.; Activation of meningeal nociceptors by cortical spreading depression: implications for migraine with aura. J Neurosci 2010,30(26),8807-8814","journal-title":"J Neurosci"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1046\/j.1468-2982.2002.00404.x","volume":"22","author":"Ferrari M.D.","year":"2002","unstructured":"Ferrari M.D.; Goadsby P.J.; Roon K.I.; Lipton R.B.; Triptans (serotonin, 5-HT1B\/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002,22(8),633-658","journal-title":"Cephalalgia"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1046\/j.1468-2982.1999.019006581.x","volume":"19","author":"Diener H.C.","year":"1999","unstructured":"Diener H.C.; Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. Cephalalgia 1999,19(6),581-588","journal-title":"Cephalalgia"},{"key":"ref=23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009108.pub2","author":"Derry C.J.","year":"2014","unstructured":"Derry C.J.; Derry S.; Moore R.A.; Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. Cochrane Database Syst Rev 2014(5)","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/S0140-6736(05)74950-3","volume":"353","author":"Limmroth V.","year":"1999","unstructured":"Limmroth V.; Kazarawa Z.; Fritsche G.; Diener H.C.; Headache after frequent use of serotonin agonists zolmitriptan and naratriptan. Lancet 1999,353(9150),378","journal-title":"Lancet"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1517\/14740338.2015.1026325","volume":"14","author":"Tajti J.","year":"2015","unstructured":"Tajti J.; Majl\u00e1th Z.; Szok D.; Cs\u00e1ti A.; V\u00e9csei L.; Drug safety in acute migraine treatment. Expert Opin Drug Saf 2015,14(6),891-909","journal-title":"Expert Opin Drug Saf"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1046\/j.1468-2982.1999.019004223.x","volume":"19","author":"O\u2019Quinn S.","year":"1999","unstructured":"O\u2019Quinn S.; Davis R.L.; Gutterman D.L.; Pait G.D.; Fox A.W.; Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for acute treatment of migraine. Cephalalgia 1999,19(4),223-231","journal-title":"Cephalalgia"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1046\/j.1468-2982.2000.00116.x","volume":"20","author":"Welch K.M.","year":"2000","unstructured":"Welch K.M.; Mathew N.T.; Stone P.; Rosamond W.; Saiers J.; Gutterman D.; Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia 2000,20(8),687-695","journal-title":"Cephalalgia"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.3390\/toxins7072615","volume":"7","author":"Schaefer S.M.","year":"2015","unstructured":"Schaefer S.M.; Gottschalk C.H.; Jabbari B.; Treatment of chronic migraine with focus on botulinum neurotoxins. Toxins (Basel) 2015,7(7),2615-2628","journal-title":"Toxins (Basel)"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.3390\/toxins7072659","volume":"7","author":"Szok D.","year":"2015","unstructured":"Szok D.; Cs\u00e1ti A.; V\u00e9csei L.; Tajti J.; Treatment of chronic migraine with Onabotulinumtoxin A: Mode of action, efficacy and safety. Toxins (Basel) 2015,7(7),2659-2673","journal-title":"Toxins (Basel)"},{"key":"ref=30","first-page":"77","volume":"65","author":"Tajti J.","year":"2012","unstructured":"Tajti J.; Szok D.; Tuka B.; Cs\u00e1ti A.; Kuris A.; Majl\u00e1th Z.; Luk\u00e1cs M.; V\u00e9csei L.; [Botulinum neurotoxin--a therapy in migraine Ideggyogy Sz 2012,65(3-4),77-82","journal-title":"Ideggyogy Sz"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.pharmthera.2012.08.011","volume":"136","author":"Edvinsson L.","year":"2012","unstructured":"Edvinsson L.; Villal\u00f3n C.M.; MaassenVanDenBrink, A. Basic mechanisms of migraine and its acute treatment. Pharmacol Ther 2012,136(3),319-333","journal-title":"Pharmacol Ther"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/brain\/88.5.997","volume":"88","author":"Curran D.A.","year":"1965","unstructured":"Curran D.A.; Hinterberger H.; Lance J.W.; Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects. Brain 1965,88(5),997-1010","journal-title":"Brain"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1476-5381.1989.tb11787.x","volume":"96","author":"Feniuk W.","year":"1989","unstructured":"Feniuk W.; Humphrey P.P.; Perren M.J.; The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetized dogs. Br J Pharmacol 1989,96(1),83-90","journal-title":"Br J Pharmacol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1046\/j.1468-2982.1997.1706631.x","volume":"17","author":"Cohen M.L.","year":"1997","unstructured":"Cohen M.L.; Johnson K.W.; Schenck K.W.; Phebus L.A.; Migraine therapy: relationship between serotonergic contractile receptors in canine and rabbit saphenous veins to human cerebral and coronary arteries. Cephalalgia 1997,17(6),631-638","journal-title":"Cephalalgia"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/sj.bjp.0702773","volume":"128","author":"Nilsson T.","year":"1999","unstructured":"Nilsson T.; Longmore J.; Shaw D.; Olesen I.J.; Edvinsson L.; Contractile 5-HT1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry. Br J Pharmacol 1999,128(6),1133-1140","journal-title":"Br J Pharmacol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1042\/CS20050016","volume":"109","author":"Edvinsson L.","year":"2005","unstructured":"Edvinsson L.; Uddman E.; Wackenfors A.; Davenport A.; Longmore J.; Malmsj\u00f6 M.; Triptan-induced contractile (5-HT1B receptor) responses in human cerebral and coronary arteries: relationship to clinical effect. Clin Sci (Lond) 2005,109(3),335-342","journal-title":"Clin Sci (Lond)"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1046\/j.1468-2982.1997.1704525.x","volume":"17","author":"Williamson D.J.","year":"1997","unstructured":"Williamson D.J.; Hargreaves R.J.; Hill R.G.; Shepheard S.L.; Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat--intravital microscope studies. Cephalalgia 1997,17(4),525-531","journal-title":"Cephalalgia"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0014-2999(97)83028-2","volume":"328","author":"Williamson D.J.","year":"1997","unstructured":"Williamson D.J.; Shepheard S.L.; Hill R.G.; Hargreaves R.J.; The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation. Eur J Pharmacol 1997,328(1),61-64","journal-title":"Eur J Pharmacol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1093\/brain\/119.5.1419","volume":"119","author":"Hoskin K.L.","year":"1996","unstructured":"Hoskin K.L.; Kaube H.; Goadsby P.J.; Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. Brain 1996,119(Pt 5),1419-1428","journal-title":"Brain"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0031-6997(25)06783-3","volume":"46","author":"Hoyer D.","year":"1994","unstructured":"Hoyer D.; Clarke D.E.; Fozard J.R.; Hartig P.R.; Martin G.R.; Mylecharane E.J.; Saxena P.R.; Humphrey P.P.; International union of pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 1994,46(2),157-203","journal-title":"Pharmacol Rev"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1471-4892(01)00003-0","volume":"1","author":"Lee D.K.","year":"2001","unstructured":"Lee D.K.; George S.R.; Evans J.F.; Lynch K.R.; O\u2019Dowd B.F.; Orphan G protein-coupled receptors in the CNS. Curr Opin Pharmacol 2001,1(1),31-39","journal-title":"Curr Opin Pharmacol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/BF00168556","volume":"352","author":"Waeber C.","year":"1995","unstructured":"Waeber C.; Moskowitz M.A.; [3H]sumatriptan labels both 5-HT1D and 5-HT1F receptor binding sites in the guinea pig brain: an autoradiographic study. Naunyn Schmiedebergs Arch Pharmacol 1995,352(3),263-275","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/brain\/123.1.9","volume":"123","author":"Tfelt-Hansen P.","year":"2000","unstructured":"Tfelt-Hansen P.; Saxena P.R.; Dahl\u00f6f C.; Pascual J.; L\u00e1inez M.; Henry P.; Diener H.; Schoenen J.; Ferrari M.D.; Goadsby P.J.; Ergotamine in the acute treatment of migraine: a review and European consensus. Brain 2000,123(Pt 1),9-18","journal-title":"Brain"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0091-3057(01)00746-8","volume":"71","author":"Hoyer D.","year":"2002","unstructured":"Hoyer D.; Hannon J.P.; Martin G.R.; Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002,71(4),533-554","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.pain.2012.01.005","volume":"153","author":"Amrutkar D.V.","year":"2012","unstructured":"Amrutkar D.V.; Ploug K.B.; Hay-Schmidt A.; Porreca F.; Olesen J.; Jansen-Olesen I.; mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system. Pain 2012,153(4),830-838","journal-title":"Pain"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.brainres.2010.09.004","volume":"1361","author":"Classey J.D.","year":"2010","unstructured":"Classey J.D.; Bartsch T.; Goadsby P.J.; Distribution of 5-HT(1B), 5-HT(1D) and 5-HT(1F) receptor expression in rat trigeminal and dorsal root ganglia neurons: relevance to the selective anti-migraine effect of triptans. Brain Res 2010,1361,76-85","journal-title":"Brain Res"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1097\/00004647-199908000-00010","volume":"19","author":"Cohen Z.","year":"1999","unstructured":"Cohen Z.; Bouchelet I.; Olivier A.; Villemure J.G.; Ball R.; Stanimirovic D.B.; Hamel E.; Multiple microvascular and astroglial 5-hydroxytryptamine receptor subtypes in human brain: molecular and pharmacologic characterization. J Cereb Blood Flow Metab 1999,19(8),908-917","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1517\/17425255.2014.963554","volume":"10","author":"Tajti J.","year":"2014","unstructured":"Tajti J.; Cs\u00e1ti A.; V\u00e9csei L.; Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors. Expert Opin Drug Metab Toxicol 2014,10(11),1509-1520","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1097\/00001756-199707070-00029","volume":"8","author":"Johnson K.W.","year":"1997","unstructured":"Johnson K.W.; Schaus J.M.; Durkin M.M.; Audia J.E.; Kaldor S.W.; Flaugh M.E.; Adham N.; Zgombick J.M.; Cohen M.L.; Branchek T.A.; Phebus L.A.; 5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Neuroreport 1997,8(9-10),2237-2240","journal-title":"Neuroreport"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00210-005-1035-9","volume":"371","author":"Wainscott D.B.","year":"2005","unstructured":"Wainscott D.B.; Krushinski J.H.; Audia J.E.; Schaus J.M.; Zgombick J.M.; Lucaites V.L.; Nelson D.L.; [3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties. Naunyn Schmiedebergs Arch Pharmacol 2005,371(3),169-177","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1046\/j.1468-2982.1999.1910851.x","volume":"19","author":"Shepheard S.","year":"1999","unstructured":"Shepheard S.; Edvinsson L.; Cumberbatch M.; Williamson D.; Mason G.; Webb J.; Boyce S.; Hill R.; Hargreaves R.; Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370. Cephalalgia 1999,19(10),851-858","journal-title":"Cephalalgia"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/sj.bjp.0703587","volume":"131","author":"Cohen M.L.","year":"2000","unstructured":"Cohen M.L.; Schenck K.; Contractile responses to sumatriptan and ergotamine in the rabbit saphenous vein: effect of selective 5-HT(1F) receptor agonists and PGF(2alpha). Br J Pharmacol 2000,131(3),562-568","journal-title":"Br J Pharmacol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/S0140-6736(01)06347-4","volume":"358","author":"Goldstein D.J.","year":"2001","unstructured":"Goldstein D.J.; Roon K.I.; Offen W.W.; Ramadan N.M.; Phebus L.A.; Johnson K.W.; Schaus J.M.; Ferrari M.D.; Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet 2001,358(9289),1230-1234","journal-title":"Lancet"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1177\/0333102410370873","volume":"30","author":"Nelson D.L.","year":"2010","unstructured":"Nelson D.L.; Phebus L.A.; Johnson K.W.; Wainscott D.B.; Cohen M.L.; Calligaro D.O.; Xu Y.C.; Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia 2010,30(10),1159-1169","journal-title":"Cephalalgia"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/13543784.2017.1280457","volume":"26","author":"Capi M.","year":"2017","unstructured":"Capi M.; de Andr\u00e9s F.; Lionetto L.; Gentile G.; Cipolla F.; Negro A.; Borro M.; Martelletti P.; Curto M.; Lasmiditan for the treatment of migraine. Expert Opin Investig Drugs 2017,26(2),227-234","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1177\/0333102410375512","volume":"30","author":"Ferrari M.D.","year":"2010","unstructured":"Ferrari M.D.; F\u00e4rkkil\u00e4 M.; Reuter U.; Pilgrim A.; Davis C.; Krauss M.; Diener H.C.; Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan--a randomised proof-of-concept trial. Cephalalgia 2010,30(10),1170-1178","journal-title":"Cephalalgia"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10194-012-0428-7","volume":"13","author":"Tfelt-Hansen P.C.","year":"2012","unstructured":"Tfelt-Hansen P.C.; Olesen J.; The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials. J Headache Pain 2012,13(4),271-275","journal-title":"J Headache Pain"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/1756285614562419","volume":"8","author":"Reuter U.","year":"2015","unstructured":"Reuter U.; Israel H.; Neeb L.; The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine. Ther Adv Neurol Disorder 2015,8(1),46-54","journal-title":"Ther Adv Neurol Disorder"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1474-4422(12)70047-9","volume":"11","author":"F\u00e4rkkil\u00e4 M.","year":"2012","unstructured":"F\u00e4rkkil\u00e4 M.; Diener H.C.; G\u00e9raud G.; L\u00e1inez M.; Schoenen J.; Harner N.; Pilgrim A.; Reuter U.; Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 2012,11(5),405-413","journal-title":"Lancet Neurol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/0333102412466967","volume":"33","author":"Bhatt D.K.","year":"2013","unstructured":"Bhatt D.K.; Gupta S.; Jansen-Olesen I.; Andrews J.S.; Olesen J.; NXN-188, a selective nNOS inhibitor and a 5-HT1B\/1D receptor agonist, inhibits CGRP release in preclinical migraine models. Cephalalgia 2013,33(2),87-100","journal-title":"Cephalalgia"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.clinthera.2010.01.006","volume":"32","author":"Vaughan D.","year":"2010","unstructured":"Vaughan D.; Speed J.; Medve R.; Andrews J.S.; Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers. Clin Ther 2010,32(1),146-160","journal-title":"Clin Ther"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.sjpain.2012.08.002","volume":"4","author":"Hougaard A.","year":"2013","unstructured":"Hougaard A.; Hauge A.W.; Guo S.; Tfelt-Hansen P.; The nitric oxide synthase inhibitor and serotonin-receptor agonist NXN-188 during the aura phase of migraine with aura: A randomized, double-blind, placebo-controlled cross-over study. Scand J Pain 2013,4(1),48-52","journal-title":"Scand J Pain"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/j.1468-2982.2008.01749.x","volume":"29","author":"Ferrari A.","year":"2009","unstructured":"Ferrari A.; Spaccapelo L.; Pinetti D.; Tacchi R.; Bertolini A.; Effective prophylactic treatments of migraine lower plasma glutamate levels. Cephalalgia 2009,29(4),423-429","journal-title":"Cephalalgia"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/j.1526-4610.2007.00812.x","volume":"47","author":"Vieira D.S.","year":"2007","unstructured":"Vieira D.S.; Naffah-Mazzacoratti, Mda.G.; Zukerman, E.; Senne Soares, C.A.; Cavalheiro, E.A.; Peres, M.F. Glutamate levels in cerebrospinal fluid and triptans overuse in chronic migraine. Headache 2007,47(6),842-847","journal-title":"Headache"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0006-8993(01)02557-4","volume":"906","author":"Gorji A.","year":"2001","unstructured":"Gorji A.; Scheller D.; Straub H.; Tegtmeier F.; K\u00f6hling R.; H\u00f6hling J.M.; Tuxhorn I.; Ebner A.; Wolf P.; Werner Panneck H.; Oppel F.; Speckmann E.J.; Spreading depression in human neocortical slices. Brain Res 2001,906(1-2),74-83","journal-title":"Brain Res"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1744-8069-4-12","volume":"4","author":"Xiao Y.","year":"2008","unstructured":"Xiao Y.; Richter J.A.; Hurley J.H.; Release of glutamate and CGRP from trigeminal ganglion neurons: Role of calcium channels and 5-HT1 receptor signaling. Mol Pain 2008,4,12","journal-title":"Mol Pain"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1111\/j.1526-4610.2006.00489.x","volume":"46","author":"Oshinsky M.L.","year":"2006","unstructured":"Oshinsky M.L.; Luo J.; Neurochemistry of trigeminal activation in an animal model of migraine. Headache 2006,46(Suppl. 1),S39-S44","journal-title":"Headache"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s10194-017-0746-x","volume":"18","author":"Luk\u00e1cs M.","year":"2017","unstructured":"Luk\u00e1cs M.; Warfvinge K.; Tajti J.; F\u00fcl\u00f6p F.; Toldi J.; V\u00e9csei L.; Edvinsson L.; Topical dura mater application of CFA induces enhanced expression of c-fos and glutamate in rat trigeminal nucleus caudalis: attenuated by KYNA derivate (SZR72). J Headache Pain 2017,18(1),39","journal-title":"J Headache Pain"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev.pa.29.040189.002053","volume":"29","author":"Monaghan D.T.","year":"1989","unstructured":"Monaghan D.T.; Bridges R.J.; Cotman C.W.; The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol 1989,29,365-402","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1124\/pr.109.002451","volume":"62","author":"Traynelis S.F.","year":"2010","unstructured":"Traynelis S.F.; Wollmuth L.P.; McBain C.J.; Menniti F.S.; Vance K.M.; Ogden K.K.; Hansen K.B.; Yuan H.; Myers S.J.; Dingledine R.; Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 2010,62(3),405-496","journal-title":"Pharmacol Rev"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1146\/annurev-physiol-030212-183711","volume":"75","author":"Kumar J.","year":"2013","unstructured":"Kumar J.; Mayer M.L.; Functional insights from glutamate receptor ion channel structures. Annu Rev Physiol 2013,75,313-337","journal-title":"Annu Rev Physiol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.coph.2006.08.011","volume":"7","author":"Paoletti P.","year":"2007","unstructured":"Paoletti P.; Neyton J.; NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol 2007,7(1),39-47","journal-title":"Curr Opin Pharmacol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00702-011-0658-x","volume":"119","author":"Kaszaki J.","year":"2012","unstructured":"Kaszaki J.; Erces D.; Varga G.; Szab\u00f3 A.; V\u00e9csei L.; Boros M.; Kynurenines and intestinal neurotransmission: the role of N-methyl-D-aspartate receptors. J Neural Transm (Vienna) 2012,119(2),211-223","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s40265-014-0262-0","volume":"74","author":"Chan K.","year":"2014","unstructured":"Chan K.; MaassenVanDenBrink, A. Glutamate receptor antagonists in the management of migraine. Drugs 2014,74(11),1165-1176","journal-title":"Drugs"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/j.cellsig.2014.04.022","volume":"26","author":"Yin S.","year":"2014","unstructured":"Yin S.; Niswender C.M.; Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indications. Cell Signal 2014,26(10),2284-2297","journal-title":"Cell Signal"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1073\/pnas.052708599","volume":"99","author":"Tsuchiya D.","year":"2002","unstructured":"Tsuchiya D.; Kunishima N.; Kamiya N.; Jingami H.; Morikawa K.; Structural views of the ligand-binding cores of a metabotropic glutamate receptor complexed with an antagonist and both glutamate and Gd. Proc Natl Acad Sci USA 2002,99(5),2660-2665","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1073\/pnas.0611577104","volume":"104","author":"Muto T.","year":"2007","unstructured":"Muto T.; Tsuchiya D.; Morikawa K.; Jingami H.; Structures of the extracellular regions of the group II\/III metabotropic glutamate receptors. Proc Natl Acad Sci USA 2007,104(10),3759-3764","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1212\/WNL.55.1.139","volume":"55","author":"Kaube H.","year":"2000","unstructured":"Kaube H.; Herzog J.; K\u00e4ufer T.; Dichgans M.; Diener H.C.; Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology 2000,55(1),139-141","journal-title":"Neurology"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1212\/WNL.0b013e3182824e66","volume":"80","author":"Afridi S.K.","year":"2013","unstructured":"Afridi S.K.; Giffin N.J.; Kaube H.; Goadsby P.J.; A ran-domized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology 2013,80(7),642-647","journal-title":"Neurology"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1124\/jpet.106.101428","volume":"318","author":"Weiss B.","year":"2006","unstructured":"Weiss B.; Alt A.; Ogden A.M.; Gates M.; Dieckman D.K.; Clemens-Smith A.; Ho K.H.; Jarvie K.; Rizkalla G.; Wright R.A.; Calligaro D.O.; Schoepp D.; Mattiuz E.L.; Stratford R.E.; Johnson B.; Salhoff C.; Katofiasc M.; Phebus L.A.; Schenck K.; Cohen M.; Filla S.A.; Ornstein P.L.; Johnson K.W.; Bleakman D.; Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo. J Pharmacol Exp Ther 2006,318(2),772-781","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/j.1468-2982.2004.00723.x","volume":"24","author":"Sang C.N.","year":"2004","unstructured":"Sang C.N.; Ramadan N.M.; Wallihan R.G.; Chappell A.S.; Freitag F.G.; Smith T.R.; Silberstein S.D.; Johnson K.W.; Phebus L.A.; Bleakman D.; Ornstein P.L.; Arnold B.; Tepper S.J.; Vandenhende F.; LY293558, a novel AMPA\/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 2004,24(7),596-602","journal-title":"Cephalalgia"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/med\/9780199552764.003.0022","author":"Johnson K.W.N.E.","year":"2008","unstructured":"Johnson K.W.N.E.; Johnson M.P.; Dieckman D.K.; Clemens-Smith A.; Siuda E.R.; Dell C.P.; Dehlinger V.; Hudziak K.J.; Filla S.A.; Ornstein P.L.; Ramadan N.M.; Bleakman D.; Innovative drug development for headache disorders: glutamateInnovative Drug Development for Headache Disorders; Olesen, J 2008,185-194","journal-title":"Innovative drug development for headache disorders: glutamateInnovative Drug Development for Headache Disorders; Olesen, J"},{"key":"ref=83","first-page":"7","volume":"29","author":"Goadsby P.J.K.C.","year":"2009","unstructured":"Goadsby P.J.K.C.; Investigation of the role of mGluR5 inhibition in migraine: a proof of concept study of ADX10059 in acute migraine treatment. Cephalalgia 2009,29(Suppl. 1),7","journal-title":"Cephalalgia"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/jcbfm.1987.126","volume":"7","author":"Edvinsson L.","year":"1987","unstructured":"Edvinsson L.; Ekman R.; Jansen I.; McCulloch J.; Uddman R.; Calcitonin gene-related peptide and cerebral blood vessels: distribution and vasomotor effects. J Cereb Blood Flow Metab 1987,7(6),720-728","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0304-3940(94)11203-U","volume":"184","author":"Knyihar-Csillik E.","year":"1995","unstructured":"Knyihar-Csillik E.; Tajti J.; Mohtasham S.; Sari G.; Vecsei L.; Electrical stimulation of the Gasserian ganglion induces structural alterations of calcitonin gene-related peptide-immunoreactive perivascular sensory nerve terminals in the rat cerebral dura mater: a possible model of migraine headache. Neurosci Lett 1995,184(3),189-192","journal-title":"Neurosci Lett"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0014-5793(86)81091-2","volume":"209","author":"Steenbergh P.H.","year":"1986","unstructured":"Steenbergh P.H.; H\u00f6ppener J.W.; Zandberg J.; Visser A.; Lips C.J.; Jansz H.S.; Structure and expression of the human calcitonin\/CGRP genes. FEBS Lett 1986,209(1),97-103","journal-title":"FEBS Lett"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1677\/joe.0.1560401","volume":"156","author":"Lou H.","year":"1998","unstructured":"Lou H.; Gagel R.F.; Alternative RNA processing--its role in regulating expression of calcitonin\/calcitonin gene-related peptide. J Endocrinol 1998,156(3),401-405","journal-title":"J Endocrinol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/0167-0115(85)90194-6","volume":"12","author":"Mulderry P.K.","year":"1985","unstructured":"Mulderry P.K.; Ghatei M.A.; Bishop A.E.; Allen Y.S.; Polak J.M.; Bloom S.R.; Distribution and chromatographic characterisation of CGRP-like immunoreactivity in the brain and gut of the rat. Regul Pept 1985,12(2),133-143","journal-title":"Regul Pept"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/sj.bjp.0704761","volume":"136","author":"Choksi T.","year":"2002","unstructured":"Choksi T.; Hay D.L.; Legon S.; Poyner D.R.; Hagner S.; Bloom S.R.; Smith D.M.; Comparison of the expression of calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) with CGRP and adrenomedullin binding in cell lines. Br J Pharmacol 2002,136(5),784-792","journal-title":"Br J Pharmacol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.tips.2010.06.006","volume":"31","author":"Walker C.S.","year":"2010","unstructured":"Walker C.S.; Conner A.C.; Poyner D.R.; Hay D.L.; Regulation of signal transduction by calcitonin gene-related peptide receptors. Trends Pharmacol Sci 2010,31(10),476-483","journal-title":"Trends Pharmacol Sci"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/ana.410280213","volume":"28","author":"Goadsby P.J.","year":"1990","unstructured":"Goadsby P.J.; Edvinsson L.; Ekman R.; Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990,28(2),183-187","journal-title":"Ann Neurol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1526-4610.2006.00294.x","volume":"46","author":"Bellamy J.L.","year":"2006","unstructured":"Bellamy J.L.; Cady R.K.; Durham P.L.; Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients. Headache 2006,46(1),24-33","journal-title":"Headache"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/0333102415625614","volume":"37","author":"van Dongen R.M.","year":"2017","unstructured":"van Dongen R.M.; Zielman R.; Noga M.; Dekkers O.M.; Hankemeier T.; van den Maagdenberg A.M.; Terwindt G.M.; Ferrari M.D.; Migraine biomarkers in cerebrospinal fluid: A systematic review and meta-analysis. Cephalalgia 2017,37(1),49-63","journal-title":"Cephalalgia"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.brainres.2014.11.031","volume":"1600","author":"Eftekhari S.","year":"2015","unstructured":"Eftekhari S.; Salvatore C.A.; Johansson S.; Chen T.B.; Zeng Z.; Edvinsson L.; Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier. Brain Res 2015,1600,93-109","journal-title":"Brain Res"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s12311-013-0509-4","volume":"12","author":"Eftekhari S.","year":"2013","unstructured":"Eftekhari S.; Salvatore C.A.; Gaspar R.C.; Roberts R.; O\u2019Malley S.; Zeng Z.; Edvinsson L.; Localization of CGRP receptor components, CGRP, and receptor binding sites in human and rhesus cerebellar cortex. Cerebellum 2013,12(6),937-949","journal-title":"Cerebellum"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.brainres.2011.11.058","volume":"1435","author":"Csati A.","year":"2012","unstructured":"Csati A.; Tajti J.; Tuka B.; Edvinsson L.; Warfvinge K.; Calcitonin gene-related peptide and its receptor components in the human sphenopalatine ganglion -- interaction with the sensory system. Brain Res 2012,1435,29-39","journal-title":"Brain Res"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/jemt.1084","volume":"53","author":"Knyih\u00e1r-Csillik E.","year":"2001","unstructured":"Knyih\u00e1r-Csillik E.; Tajti J.; Chadaide Z.; Csillik B.; V\u00e9csei L.; Functional immunohistochemistry of neuropeptides and nitric oxide synthase in the nerve fibers of the supratentorial dura mater in an experimental migraine model. Microsc Res Tech 2001,53(3),193-211","journal-title":"Microsc Res Tech"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1186\/s10194-015-0564-y","volume":"16","author":"Luk\u00e1cs M.","year":"2015","unstructured":"Luk\u00e1cs M.; Haanes K.A.; Majl\u00e1th Z.; Tajti J.; V\u00e9csei L.; Warfvinge K.; Edvinsson L.; Dural administration of inflammatory soup or Complete Freund\u2019s Adjuvant induces activation and inflammatory response in the rat trigeminal ganglion. J Headache Pain 2015,16,564","journal-title":"J Headache Pain"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/0333102410382796","volume":"31","author":"Tajti J.","year":"2011","unstructured":"Tajti J.; Kuris A.; V\u00e9csei L.; Xu C.B.; Edvinsson L.; Organ culture of the trigeminal ganglion induces enhanced expression of calcitonin gene-related peptide via activation of extracellular signal-regulated protein kinase 1\/2. Cephalalgia 2011,31(1),95-105","journal-title":"Cephalalgia"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.neulet.2009.11.035","volume":"469","author":"Hou J.F.","year":"2010","unstructured":"Hou J.F.; Yu L.C.; Blockade effects of BIBN4096BS on CGRP-induced inhibition on whole-cell K currents in spinal dorsal horn neuron of rats. Neurosci Lett 2010,469(1),15-18","journal-title":"Neurosci Lett"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/j.1468-2982.2004.00726.x","volume":"24","author":"Iovino M.","year":"2004","unstructured":"Iovino M.; Feifel U.; Yong C.L.; Wolters J.M.; Wallenstein G.; Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia 2004,24(8),645-656","journal-title":"Cephalalgia"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1056\/NEJMoa030505","volume":"350","author":"Olesen J.","year":"2004","unstructured":"Olesen J.; Diener H.C.; Husstedt I.W.; Goadsby P.J.; Hall D.; Meier U.; Pollentier S.; Lesko L.M.; Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004,350(11),1104-1110","journal-title":"N Engl J Med"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1517\/13543784.2015.960921","volume":"24","author":"V\u00e9csei L.","year":"2015","unstructured":"V\u00e9csei L.; Szok D.; Cs\u00e1ti A.; Tajti J.; CGRP antagonists and antibodies for the treatment of migraine. Expert Opin Investig Drugs 2015,24(1),31-41","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1177\/0333102410362122","volume":"30","author":"Edvinsson L.","year":"2010","unstructured":"Edvinsson L.; Chan K.Y.; Eftekhari S.; Nilsson E.; de Vries R.; S\u00e4veland H.; Dirven C.M.; Danser A.H.; MaassenVanDenBrink, A. Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries. Cephalalgia 2010,30(10),1233-1240","journal-title":"Cephalalgia"},{"key":"ref=105","first-page":"711","volume":"10","author":"Tepper S.J.","year":"2009","unstructured":"Tepper S.J.; Cleves C.; Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine. Curr Opin Investig Drugs 2009,10(7),711-720","journal-title":"Curr Opin Investig Drugs"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1152\/physrev.00034.2015","volume":"97","author":"Goadsby P.J.","year":"2017","unstructured":"Goadsby P.J.; Holland P.R.; Martins-Oliveira M.; Hoffmann J.; Schankin C.; Akerman S.; Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev 2017,97(2),553-622","journal-title":"Physiol Rev"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/0333102413500727","volume":"34","author":"Marcus R.","year":"2014","unstructured":"Marcus R.; Goadsby P.J.; Dodick D.; Stock D.; Manos G.; Fischer T.Z.; BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 2014,34(2),114-125","journal-title":"Cephalalgia"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/0333102410388435","volume":"31","author":"Diener H.C.","year":"2011","unstructured":"Diener H.C.; Barbanti P.; Dahl\u00f6f C.; Reuter U.; Habeck J.; Podhorna J.; BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 2011,31(5),573-584","journal-title":"Cephalalgia"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1177\/0333102416653233","volume":"36","author":"Voss T.","year":"2016","unstructured":"Voss T.; Lipton R.B.; Dodick D.W.; Dupre N.; Ge J.Y.; Bachman R.; Assaid C.; Aurora S.K.; Michelson D.; A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia 2016,36(9),887-898","journal-title":"Cephalalgia"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40263-015-0253-z","volume":"29","author":"Wrobel Goldberg S.","year":"2015","unstructured":"Wrobel Goldberg S.; Silberstein S.D.; Targeting CGRP: A new era for migraine treatment. CNS Drugs 2015,29(6),443-452","journal-title":"CNS Drugs"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/cpdd.345","volume":"6","author":"Pellesi L.","year":"2017","unstructured":"Pellesi L.; Guerzoni S.; Pini L.A.; Spotlight on Anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date. Clin Pharmacol Drug Dev 2017,6(6),534-547","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/bcp.12618","volume":"80","author":"Edvinsson L.","year":"2015","unstructured":"Edvinsson L.; CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol 2015,80(2),193-199","journal-title":"Br J Clin Pharmacol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1177\/1078155214538085","volume":"21","author":"Azanza J.R.","year":"2015","unstructured":"Azanza J.R.; S\u00e1daba B.; G\u00f3mez-Guiu A.; Monoclonal antibodies: pharmacokinetics as a basis for new dosage regimens? J Oncol Pharm Pract 2015,21(5),370-376","journal-title":"J Oncol Pharm Pract"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40263-014-0156-4","volume":"28","author":"Bigal M.E.","year":"2014","unstructured":"Bigal M.E.; Walter S.; Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs 2014,28(5),389-399","journal-title":"CNS Drugs"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1146\/annurev-pharmtox-010510-100510","volume":"51","author":"Zhou H.","year":"2011","unstructured":"Zhou H.; Mascelli M.A.; Mechanisms of monoclonal antibody-drug interactions. Annu Rev Pharmacol Toxicol 2011,51,359-372","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4161\/mabs.1.2.7909","volume":"1","author":"Descotes J.","year":"2009","unstructured":"Descotes J.; Immunotoxicity of monoclonal antibodies. MAbs 2009,1(2),104-111","journal-title":"MAbs"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0300-483X(02)00051-3","volume":"174","author":"Vial T.","year":"2002","unstructured":"Vial T.; Choquet-Kastylevsky G.; Descotes J.; Adverse effects of immunotherapeutics involving the immune system. Toxicology 2002,174(1),3-11","journal-title":"Toxicology"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/00042737-200406000-00018","volume":"16","author":"Stallmach A.","year":"2004","unstructured":"Stallmach A.; Giese T.; Schmidt C.; Meuer S.C.; Zeuzem S.S.; Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case. Eur J Gastroenterol Hepatol 2004,16(6),627-630","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S1474-4422(14)70128-0","volume":"13","author":"Dodick D.W.","year":"2014","unstructured":"Dodick D.W.; Goadsby P.J.; Spierings E.L.; Scherer J.C.; Sweeney S.P.; Grayzel D.S.; Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 2014,13(9),885-892","journal-title":"Lancet Neurol"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S1474-4422(14)70309-6","volume":"14","author":"Dodick D.W.","year":"2015","unstructured":"Dodick D.W.; Goadsby P.J.; Spierings E.L.; Scherer J.C.; Sweeney S.P.; Grayzel D.S.; Site of effect of LY2951742 for migraine prophylaxis--authors\u2019 reply. Lancet Neurol 2015,14(1),32-33","journal-title":"Lancet Neurol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(16)00019-3","volume":"15","author":"Sun H.","year":"2016","unstructured":"Sun H.; Dodick D.W.; Silberstein S.; Goadsby P.J.; Reuter U.; Ashina M.; Saper J.; Cady R.; Chon Y.; Dietrich J.; Lenz R.; Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 2016,15(4),382-390","journal-title":"Lancet Neurol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1474-4422(15)00249-5","volume":"14","author":"Bigal M.E.","year":"2015","unstructured":"Bigal M.E.; Dodick D.W.; Rapoport A.M.; Silberstein S.D.; Ma Y.; Yang R.; Loupe P.S.; Burstein R.; Newman L.C.; Lipton R.B.; Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 2015,14(11),1081-1090","journal-title":"Lancet Neurol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(15)00245-8","volume":"14","author":"Bigal M.E.","year":"2015","unstructured":"Bigal M.E.; Edvinsson L.; Rapoport A.M.; Lipton R.B.; Spierings E.L.; Diener H.C.; Burstein R.; Loupe P.S.; Ma Y.; Yang R.; Silberstein S.D.; Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 2015,14(11),1091-1100","journal-title":"Lancet Neurol"},{"volume":"37","year":"2017","key":"ref=124","unstructured":"IHC oral abstracts and posters, Cephalalgia, 2017,37(Issue 1_suppl)"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1468-1331.2011.03612.x","volume":"19","author":"Linde M.","year":"2012","unstructured":"Linde M.; Gustavsson A.; Stovner L.J.; Steiner T.J.; Barr\u00e9 J.; Katsarava Z.; Lainez J.M.; Lampl C.; Lant\u00e9ri-Minet M.; Rastenyte D.; Ruiz de la Torre E.; Tassorelli C.; Andr\u00e9e C.; The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 2012,19(5),703-711","journal-title":"Eur J Neurol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/0006-291X(89)91757-9","volume":"164","author":"Miyata A.","year":"1989","unstructured":"Miyata A.; Arimura A.; Dahl R.R.; Minamino N.; Uehara A.; Jiang L.; Culler M.D.; Coy D.H.; Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 1989,164(1),567-574","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.peptides.2016.03.003","volume":"79","author":"Emery A.C.","year":"2016","unstructured":"Emery A.C.; Alvarez R.A.; Abboud P.; Xu W.; Westover C.D.; Eiden M.V.; Eiden L.E.; C-terminal amidation of PACAP-38 and PACAP-27 is dispensable for biological activity at the PAC1 receptor. Peptides 2016,79,39-48","journal-title":"Peptides"},{"key":"ref=128","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S0022-3565(25)39457-7","volume":"267","author":"Banks W.A.","year":"1993","unstructured":"Banks W.A.; Kastin A.J.; Komaki G.; Arimura A.; Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier. J Pharmacol Exp Ther 1993,267(2),690-696","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.2174\/0929867324666170227115019","volume":"24","author":"Tajti J.","year":"2017","unstructured":"Tajti J.; Szok D.; Nagy-Grocz G.; Tuka B.; Petrovics-Balog A.; Toldi J.; Vecsei L.; Kynurenines and PACAP in migraine: medicinal chemistry and pathogenetic aspects. Curr Med Chem 2017,24(13),1332-1349","journal-title":"Curr Med Chem"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/brain\/awu014","volume":"137","author":"V\u00e9csei L.","year":"2014","unstructured":"V\u00e9csei L.; Tuka B.; Tajti J.; Role of PACAP in migraine headaches. Brain 2014,137(Pt 3),650-651","journal-title":"Brain"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1046\/j.1468-2982.2001.00140.x","volume":"21","author":"Tajti J.","year":"2001","unstructured":"Tajti J.; Uddman R.; Edvinsson L.; Neuropeptide localization in the \u201cmigraine generator\u201d region of the human brainstem. Cephalalgia 2001,21(2),96-101","journal-title":"Cephalalgia"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0165-1838(99)00024-7","volume":"76","author":"Tajti J.","year":"1999","unstructured":"Tajti J.; Uddman R.; M\u00f6ller S.; Sundler F.; Edvinsson L.; Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst 1999,76(2-3),176-183","journal-title":"J Auton Nerv Syst"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1046\/j.1468-2982.2002.00324.x","volume":"22","author":"Uddman R.","year":"2002","unstructured":"Uddman R.; Tajti J.; Hou M.; Sundler F.; Edvinsson L.; Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2. Cephalalgia 2002,22(2),112-116","journal-title":"Cephalalgia"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0006-8993(99)01260-3","volume":"826","author":"Uddman R.","year":"1999","unstructured":"Uddman R.; Tajti J.; M\u00f6ller S.; Sundler F.; Edvinsson L.; Neuronal messengers and peptide receptors in the human sphenopalatine and otic ganglia. Brain Res 1999,826(2),193-199","journal-title":"Brain Res"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s10194-016-0664-3","volume":"17","author":"Steinberg A.","year":"2016","unstructured":"Steinberg A.; Frederiksen S.D.; Blixt F.W.; Warfvinge K.; Edvinsson L.; Expression of messenger molecules and receptors in rat and human sphenopalatine ganglion indicating therapeutic targets. J Headache Pain 2016,17(1),78","journal-title":"J Headache Pain"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1177\/0333102413483931","volume":"33","author":"Tuka B.","year":"2013","unstructured":"Tuka B.; Helyes Z.; Markovics A.; Bagoly T.; Szolcs\u00e1nyi J.; Szab\u00f3 N.; T\u00f3th E.; Kincses Z.T.; V\u00e9csei L.; Tajti J.; Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia 2013,33(13),1085-1095","journal-title":"Cephalalgia"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s10194-016-0660-7","volume":"17","author":"Tuka B.","year":"2016","unstructured":"Tuka B.; Szab\u00f3 N.; T\u00f3th E.; Kincses Z.T.; P\u00e1rdutz \u00c1.; Szok D.; K\u00f6rt\u00e9si T.; Bagoly T.; Helyes Z.; Edvinsson L.; V\u00e9csei L.; Tajti J.; Release of PACAP-38 in episodic cluster headache patients - an exploratory study. J Headache Pain 2016,17(1),69","journal-title":"J Headache Pain"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1212\/WNL.0000000000002261","volume":"86","author":"Amin F.M.","year":"2016","unstructured":"Amin F.M.; Hougaard A.; Magon S.; Asghar M.S.; Ahmad N.N.; Rostrup E.; Sprenger T.; Ashina M.; Change in brain network connectivity during PACAP38-induced migraine attacks: A resting-state functional MRI study. Neurology 2016,86(2),180-187","journal-title":"Neurology"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.nurt.2010.02.003","volume":"7","author":"Schytz H.W.","year":"2010","unstructured":"Schytz H.W.; Olesen J.; Ashina M.; The PACAP receptor: a novel target for migraine treatment. Neurotherapeutics 2010,7(2),191-196","journal-title":"Neurotherapeutics"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/j.peptides.2007.04.026","volume":"28","author":"Laburthe M.","year":"2007","unstructured":"Laburthe M.; Couvineau A.; Tan V.; Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides 2007,28(9),1631-1639","journal-title":"Peptides"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0167-0115(98)00147-5","volume":"79","author":"Sch\u00e4fer H.","year":"1999","unstructured":"Sch\u00e4fer H.; Zheng J.; Morys-Wortmann C.; F\u00f6lsch U.R.; Schmidt W.E.; Structural motifs of pituitary adenylate cyclase-activating polypeptide (PACAP) defining PAC1-receptor selectivity. Regul Pept 1999,79(2-3),83-92","journal-title":"Regul Pept"},{"key":"ref=142","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa7557","volume":"7","author":"Akerman S.","year":"2015","unstructured":"Akerman S.; Goadsby P.J.; Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: Relevance to migraine. Sci Transl Med 2015,7(308)","journal-title":"Sci Transl Med"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jpain.2008.01.329","volume":"9","author":"Davis-Taber R.","year":"2008","unstructured":"Davis-Taber R.; Baker S.; Lehto S.G.; Zhong C.; Surowy C.S.; Faltynek C.R.; Scott V.E.; Honore P.; Central pituitary adenylate cyclase 1 receptors modulate nociceptive behaviors in both inflammatory and neuropathic pain states. J Pain 2008,9(5),449-456","journal-title":"J Pain"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1177\/0333102416644435","volume":"37","author":"Vollesen A.L.","year":"2017","unstructured":"Vollesen A.L.; Guo S.; Ashina M.; PACAP38 dose-response pilot study in migraine patients. Cephalalgia 2017,37(4),391-395","journal-title":"Cephalalgia"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nrd3793","volume":"12","author":"V\u00e9csei L.","year":"2013","unstructured":"V\u00e9csei L.; Szal\u00e1rdy L.; F\u00fcl\u00f6p F.; Toldi J.; Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov 2013,12(1),64-82","journal-title":"Nat Rev Drug Discov"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"9772","DOI":"10.3390\/ijms16059772","volume":"16","author":"Boh\u00e1r Z.","year":"2015","unstructured":"Boh\u00e1r Z.; Toldi J.; F\u00fcl\u00f6p F.; V\u00e9csei L.; Changing the face of kynurenines and neurotoxicity: therapeutic considerations. Int J Mol Sci 2015,16(5),9772-9793","journal-title":"Int J Mol Sci"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.neuint.2006.08.012","volume":"50","author":"Hartai Z.","year":"2007","unstructured":"Hartai Z.; Juh\u00e1sz A.; Riman\u00f3czy A.; Jan\u00e1ky T.; Donk\u00f3 T.; Dux L.; Penke B.; T\u00f3th G.K.; Janka Z.; K\u00e1lm\u00e1n J.; Decreased serum and red blood cell kynurenic acid levels in Alzheimer\u2019s disease. Neurochem Int 2007,50(2),308-313","journal-title":"Neurochem Int"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00702-011-0697-3","volume":"119","author":"Z\u00e1dori D.","year":"2012","unstructured":"Z\u00e1dori D.; Kliv\u00e9nyi P.; Toldi J.; F\u00fcl\u00f6p F.; V\u00e9csei L.; Kynurenines in Parkinson\u2019s disease: therapeutic perspectives. J Neural Transm (Vienna) 2012,119(2),275-283","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.2174\/092986712800167365","volume":"19","author":"Szalardy L.","year":"2012","unstructured":"Szalardy L.; Klivenyi P.; Zadori D.; Fulop F.; Toldi J.; Vecsei L.; Mitochondrial disturbances, tryptophan metabolites and neurodegeneration: medicinal chemistry aspects. Curr Med Chem 2012,19(13),1899-1920","journal-title":"Curr Med Chem"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0304-3940(02)00710-3","volume":"331","author":"Rejdak K.","year":"2002","unstructured":"Rejdak K.; Bartosik-Psujek H.; Dobosz B.; Kocki T.; Grieb P.; Giovannoni G.; Turski W.A.; Stelmasiak Z.; Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients. Neurosci Lett 2002,331(1),63-65","journal-title":"Neurosci Lett"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"376","DOI":"10.2174\/157015911795596621","volume":"9","author":"Fejes A.","year":"2011","unstructured":"Fejes A.; P\u00e1rdutz A.; Toldi J.; V\u00e9csei L.; Kynurenine metabolites and migraine: experimental studies and therapeutic perspectives. Curr Neuropharmacol 2011,9(2),376-387","journal-title":"Curr Neuropharmacol"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.neulet.2006.03.051","volume":"402","author":"Prescott C.","year":"2006","unstructured":"Prescott C.; Weeks A.M.; Staley K.J.; Partin K.M.; Kynurenic acid has a dual action on AMPA receptor responses. Neurosci Lett 2006,402(1-2),108-112","journal-title":"Neurosci Lett"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s00702-008-0052-5","volume":"115","author":"R\u00f3zsa E.","year":"2008","unstructured":"R\u00f3zsa E.; Robotka H.; V\u00e9csei L.; Toldi J.; The Janus-face kynurenic acid. J Neural Transm (Vienna) 2008,115(8),1087-1091","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0361-9230(92)90184-Y","volume":"28","author":"V\u00e9csei L.","year":"1992","unstructured":"V\u00e9csei L.; Miller J.; MacGarvey U.; Beal M.F.; Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain. Brain Res Bull 1992,28(2),233-238","journal-title":"Brain Res Bull"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.neuropharm.2009.06.033","volume":"57","author":"V\u00e1mos E.","year":"2009","unstructured":"V\u00e1mos E.; P\u00e1rdutz A.; Varga H.; Boh\u00e1r Z.; Tajti J.; F\u00fcl\u00f6p F.; Toldi J.; V\u00e9csei L.; l-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus. Neuropharmacology 2009,57(4),425-429","journal-title":"Neuropharmacology"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00702-006-0545-z","volume":"114","author":"Knyih\u00e1r-Csillik E.","year":"2007","unstructured":"Knyih\u00e1r-Csillik E.; Toldi J.; Mih\u00e1ly A.; Krisztin-P\u00e9va B.; Chadaide Z.; N\u00e9meth H.; Fenyo R.; V\u00e9csei L.; Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c-fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine model. J Neural Transm (Vienna) 2007,114(4),417-421","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"4378","DOI":"10.1021\/jm970467t","volume":"40","author":"R\u00f6ver S.","year":"1997","unstructured":"R\u00f6ver S.; Cesura A.M.; Huguenin P.; Kettler R.; Szente A.; Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J Med Chem 1997,40(26),4378-4385","journal-title":"J Med Chem"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0960-894X(01)00758-2","volume":"12","author":"Walsh H.A.","year":"2002","unstructured":"Walsh H.A.; Leslie P.L.; O\u2019Shea K.C.; Botting N.P.; 2-Amino-4-[3\u2032-hydroxyphenyl]-4-hydroxybutanoic acid; a potent inhibitor of rat and recombinant human kynureninase. Bioorg Med Chem Lett 2002,12(3),361-363","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ejphar.2011.05.069","volume":"667","author":"Gell\u00e9rt L.","year":"2011","unstructured":"Gell\u00e9rt L.; Fuzik J.; G\u00f6bl\u00f6s A.; S\u00e1rk\u00f6zi K.; Marosi M.; Kis Z.; Farkas T.; Szatm\u00e1ri I.; F\u00fcl\u00f6p F.; V\u00e9csei L.; Toldi J.; Neuroprotection with a new kynurenic acid analog in the four-vessel occlusion model of ischemia. Eur J Pharmacol 2011,667(1-3),182-187","journal-title":"Eur J Pharmacol"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00702-010-0573-6","volume":"118","author":"Z\u00e1dori D.","year":"2011","unstructured":"Z\u00e1dori D.; Nyiri G.; Szonyi A.; Szatm\u00e1ri I.; F\u00fcl\u00f6p F.; Toldi J.; Freund T.F.; V\u00e9csei L.; Kliv\u00e9nyi P.; Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington\u2019s disease. J Neural Transm (Vienna) 2011,118(6),865-875","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00702-011-0755-x","volume":"119","author":"Demeter I.","year":"2012","unstructured":"Demeter I.; Nagy K.; Gell\u00e9rt L.; V\u00e9csei L.; F\u00fcl\u00f6p F.; Toldi J.; A novel kynurenic acid analog (SZR104) inhibits pentylenetetrazole-induced epileptiform seizures. An electrophysiological study: special issue related to kynurenine. J Neural Transm (Vienna) 2012,119(2),151-154","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s10194-016-0654-5","volume":"17","author":"Luk\u00e1cs M.","year":"2016","unstructured":"Luk\u00e1cs M.; Warfvinge K.; Kruse L.S.; Tajti J.; F\u00fcl\u00f6p F.; Toldi J.; V\u00e9csei L.; Edvinsson L.; KYNA analogue SZR72 modifies CFA-induced dural inflammation- regarding expression of pERK1\/2 and IL-1\u03b2 in the rat trigeminal ganglion. J Headache Pain 2016,17(1),64","journal-title":"J Headache Pain"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s10194-015-0581-x","volume":"16","author":"Cs\u00e1ti A.","year":"2015","unstructured":"Cs\u00e1ti A.; Edvinsson L.; V\u00e9csei L.; Toldi J.; F\u00fcl\u00f6p F.; Tajti J.; Warfvinge K.; Kynurenic acid modulates experimentally induced inflammation in the trigeminal ganglion. J Headache Pain 2015,16,99","journal-title":"J Headache Pain"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.2174\/092986709789909602","volume":"16","author":"F\u00fcl\u00f6p F.","year":"2009","unstructured":"F\u00fcl\u00f6p F.; Szatm\u00e1ri I.; V\u00e1mos E.; Z\u00e1dori D.; Toldi J.; V\u00e9csei L.; Syntheses, transformations and pharmaceutical applications of kynurenic acid derivatives. Curr Med Chem 2009,16(36),4828-4842","journal-title":"Curr Med Chem"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00702-011-0721-7","volume":"119","author":"F\u00fcl\u00f6p F.","year":"2012","unstructured":"F\u00fcl\u00f6p F.; Szatm\u00e1ri I.; Toldi J.; V\u00e9csei L.; Modifications on the carboxylic function of kynurenic acid. J Neural Transm (Vienna) 2012,119(2),109-114","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00702-016-1615-5","volume":"124","author":"Veres G.","year":"2017","unstructured":"Veres G.; Fejes-Szab\u00f3 A.; Z\u00e1dori D.; Nagy-Gr\u00f3cz G.; L\u00e1szl\u00f3 A.M.; Bajtai A.; M\u00e1ndity I.; Szentirmai M.; Boh\u00e1r Z.; Laborc K.; Szatm\u00e1ri I.; F\u00fcl\u00f6p F.; V\u00e9csei L.; P\u00e1rdutz \u00c1.; A comparative assessment of two kynurenic acid analogs in the formalin model of trigeminal activation: a behavioral, immunohistochemical and pharmacokinetic study. J Neural Transm (Vienna) 2017,124(1),99-112","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jpba.2011.02.014","volume":"55","author":"Z\u00e1dori D.","year":"2011","unstructured":"Z\u00e1dori D.; Ilisz I.; Kliv\u00e9nyi P.; Szatm\u00e1ri I.; F\u00fcl\u00f6p F.; Toldi J.; V\u00e9csei L.; P\u00e9ter A.; Time-course of kynurenic acid concentration in mouse serum following the administration of a novel kynurenic acid analog. J Pharm Biomed Anal 2011,55(3),540-543","journal-title":"J Pharm Biomed Anal"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00702-013-1146-2","volume":"121","author":"Fejes-Szab\u00f3 A.","year":"2014","unstructured":"Fejes-Szab\u00f3 A.; Boh\u00e1r Z.; V\u00e1mos E.; Nagy-Gr\u00f3cz G.; Tar L.; Veres G.; Z\u00e1dori D.; Szentirmai M.; Tajti J.; Szatm\u00e1ri I.; F\u00fcl\u00f6p F.; Toldi J.; P\u00e1rdutz \u00c1.; V\u00e9csei L.; Pre-treatment with new kynurenic acid amide dose-dependently prevents the nitroglycerine-induced neuronal activation and sensitization in cervical part of trigemino-cervical complex. J Neural Transm (Vienna) 2014,121(7),725-738","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.2174\/0929867324666170712163437","volume":"24","author":"Lukacs M.","year":"2017","unstructured":"Lukacs M.; Tajti J.; Fulop F.; Toldi J.; Edvinsson L.; Vecsei L.; Migraine, neurogenic inflammation, drug development - pharmacochemical aspects. Curr Med Chem 2017,24(33),3649-3665","journal-title":"Curr Med Chem"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/39807","volume":"389","author":"Caterina M.J.","year":"1997","unstructured":"Caterina M.J.; Schumacher M.A.; Tominaga M.; Rosen T.A.; Levine J.D.; Julius D.; The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997,389(6653),816-824","journal-title":"Nature"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0896-6273(02)00908-X","volume":"36","author":"Ji R.R.","year":"2002","unstructured":"Ji R.R.; Samad T.A.; Jin S.X.; Schmoll R.; Woolf C.J.; p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 2002,36(1),57-68","journal-title":"Neuron"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1254\/jphs.12276FP","volume":"122","author":"Kitagawa Y.","year":"2013","unstructured":"Kitagawa Y.; Tamai I.; Hamada Y.; Usui K.; Wada M.; Sakata M.; Matsushita M.; Orally administered selective TRPV1 antagonist, JTS-653, attenuates chronic pain refractory to non-steroidal anti-inflammatory drugs in rats and mice including post-herpetic pain. J Pharmacol Sci 2013,122(2),128-137","journal-title":"J Pharmacol Sci"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1177\/0333102410375626","volume":"31","author":"Summ O.","year":"2011","unstructured":"Summ O.; Holland P.R.; Akerman S.; Goadsby P.J.; TRPV1 receptor blockade is ineffective in different in vivo models of migraine. Cephalalgia 2011,31(2),172-180","journal-title":"Cephalalgia"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00210-009-0437-5","volume":"380","author":"Lambert G.A.","year":"2009","unstructured":"Lambert G.A.; Davis J.B.; Appleby J.M.; Chizh B.A.; Hoskin K.L.; Zagami A.S.; The effects of the TRPV1 receptor antagonist SB-705498 on trigeminovascular sensitisation and neurotransmission. Naunyn Schmiedebergs Arch Pharmacol 2009,380(4),311-325","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1124\/jpet.106.116657","volume":"321","author":"Gunthorpe M.J.","year":"2007","unstructured":"Gunthorpe M.J.; Hannan S.L.; Smart D.; Jerman J.C.; Arpino S.; Smith G.D.; Brough S.; Wright J.; Egerton J.; Lappin S.C.; Holland V.A.; Winborn K.; Thompson M.; Rami H.K.; Randall A.; Davis J.B.; Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1\/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor. J Pharmacol Exp Ther 2007,321(3),1183-1192","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"S202a","DOI":"10.1016\/S1090-3801(09)60705-9","volume":"13","author":"Chizh B.P.J.","year":"2009","unstructured":"Chizh B.P.J.; Lai R.; Guillard F.; Bullman J.; Baines A.; Napolitano A.; Appleby J.; A randomised, two-period cross-over study to investigate the efficacy of the Trpv1 antagonist SB-705498 in acute migraine. Eur J Pain 2009,13,S202a-S202","journal-title":"Eur J Pain"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/978-1-4757-0154-8_18","volume":"198","author":"Sicuteri F.","year":"1986","unstructured":"Sicuteri F.; Renzi D.; Geppetti P.; Substance P and enkephalins: a creditable tandem in the pathophysiology of cluster headache and migraine. Adv Exp Med Biol 1986,198(Pt B),145-152","journal-title":"Adv Exp Med Biol"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/j.1476-5381.1994.tb13168.x","volume":"112","author":"Lee W.S.","year":"1994","unstructured":"Lee W.S.; Moussaoui S.M.; Moskowitz M.A.; Blockade by oral or parenteral RPR 100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea-pig dura mater and conjunctiva. Br J Pharmacol 1994,112(3),920-924","journal-title":"Br J Pharmacol"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1046\/j.1468-2982.2003.00496.x","volume":"23","author":"Diener H.C.","year":"2003","unstructured":"Diener H.C.; Group R.P.R.S.; RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Cephalalgia 2003,23(3),183-185","journal-title":"Cephalalgia"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1046\/j.1468-2982.2001.00161.x","volume":"21","author":"Goldstein D.J.","year":"2001","unstructured":"Goldstein D.J.; Offen W.W.; Klein E.G.; Phebus L.A.; Hipskind P.; Johnson K.W.; Ryan R.E.; Jr. Lanepitant, an NK-1 antagonist, in migraine prevention. Cephalalgia 2001,21(2),102-106","journal-title":"Cephalalgia"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1468-2982.2004.00863.x","volume":"25","author":"Taffi R.","year":"2005","unstructured":"Taffi R.; Vignini A.; Lanciotti C.; Luconi R.; Nanetti L.; Mazzanti L.; Provinciali L.; Silvestrini M.; Bartolini M.; Platelet membrane fluidity and peroxynitrite levels in migraine patients during headache-free periods. Cephalalgia 2005,25(5),353-358","journal-title":"Cephalalgia"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1046\/j.1468-2982.2003.00586.x","volume":"23","author":"Lassen L.H.","year":"2003","unstructured":"Lassen L.H.; Christiansen I.; Iversen H.K.; Jansen-Olesen I.; Olesen J.; The effect of nitric oxide synthase inhibition on histamine induced headache and arterial dilatation in migraineurs. Cephalalgia 2003,23(9),877-886","journal-title":"Cephalalgia"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/sj.bjp.0706168","volume":"145","author":"Alderton W.K.","year":"2005","unstructured":"Alderton W.K.; Angell A.D.; Craig C.; Dawson J.; Garvey E.; Moncada S.; Monkhouse J.; Rees D.; Russell L.J.; Russell R.J.; Schwartz S.; Waslidge N.; Knowles R.G.; GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. Br J Pharmacol 2005,145(3),301-312","journal-title":"Br J Pharmacol"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1177\/0091270008329548","volume":"49","author":"Van der Schueren B.J.","year":"2009","unstructured":"Van der Schueren B.J.; Lunnon M.W.; Laurijssens B.E.; Guillard F.; Palmer J.; Van Hecken A.; Depr\u00e9 M.; Vanmolkot F.H.; de Hoon J.N.; Does the unfavorable pharmacokinetic and pharmacodynamic profile of the iNOS inhibitor GW273629 lead to inefficacy in acute migraine? J Clin Pharmacol 2009,49(3),281-290","journal-title":"J Clin Pharmacol"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1073\/pnas.95.1.322","volume":"95","author":"de Lecea L.","year":"1998","unstructured":"de Lecea L.; Kilduff T.S.; Peyron C.; Gao X.; Foye P.E.; Danielson P.E.; Fukuhara C.; Battenberg E.L.; Gautvik V.T.; Bartlett F.S.; Frankel W.N.; van den Pol A.N.; Bloom F.E.; Gautvik K.M.; Sutcliffe J.G.; The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 1998,95(1),322-327","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1749-6632.2010.05513.x","volume":"1200","author":"Sakurai T.","year":"2010","unstructured":"Sakurai T.; Mieda M.; Tsujino N.; The orexin system: roles in sleep\/wake regulation. Ann N Y Acad Sci 2010,1200,149-161","journal-title":"Ann N Y Acad Sci"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1111\/j.1460-9568.2006.05168.x","volume":"24","author":"Holland P.R.","year":"2006","unstructured":"Holland P.R.; Akerman S.; Goadsby P.J.; Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. Eur J Neurosci 2006,24(10),2825-2833","journal-title":"Eur J Neurosci"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1177\/0333102414544979","volume":"35","author":"Chabi A.","year":"2015","unstructured":"Chabi A.; Zhang Y.; Jackson S.; Cady R.; Lines C.; Herring W.J.; Connor K.M.; Michelson D.; Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis. Cephalalgia 2015,35(5),379-388","journal-title":"Cephalalgia"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/162570","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T22:12:40Z","timestamp":1751667160000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/162570\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,12]]},"references-count":188,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2019,12,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867325666180530114534","relation":{},"ISSN":["0929-8673"],"issn-type":[{"type":"print","value":"0929-8673"}],"subject":[],"published":{"date-parts":[[2019,12,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-10-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}